Key result
Whole-body FDG PET underperforms MRI and chest CT in detecting local recurrence and lung metastases.
Why the study?
The ability of whole-body 18F-fluorodeoxyglucose positron emission tomography (FDG PET) to identify local recurrence and pulmonary metastases in soft-tissue sarcoma patients after treatment was evaluated.
Does FDG PET accurately detect local recurrence and pulmonary metastases compared to MRI and CT in patients with treated soft-tissue sarcomas?
Population
62 patients with 15 types of soft-tissue sarcoma after treatment, mean age 51 years
Comparison
FDG PET vs MRI for local recurrence and vs CT of the chest for pulmonary metastases
Design
Retrospective observational analysis
Follow-up
Mean 3 years 2 months
Authors
Loading...
FDG PET's lower sensitivity cautions against replacing MRI or CT; leaves open its role as one-step surveillance in treated sarcomas.
Observational (n=62)
Does FDG PET accurately detect local recurrence and pulmonary metastases compared to MRI and CT in patients with treated soft-tissue sarcomas?
FDG PET can identify both local and distant recurrence of soft-tissue sarcomas as a one-step procedure, though MRI and CT remain necessary for accurate disease extent definition.
Lucas et al. (1998) conducted an observational in Soft-tissue sarcomas (n=62). 18F-fluorodeoxyglucose positron emission tomography (FDG PET) vs. MRI and chest CT was evaluated on Detection of local recurrence and pulmonary metastases. Whole-body FDG PET detected local recurrence with 73.7% sensitivity and lung metastases with 86.7% sensitivity, compared to 88.2% for MRI and 100% for chest CT, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: